Early evidence suggests psychedelics could help alleviate end-of-life anxiety and depression. Yet there has been little study or discussion of their integration into hospice and palliative care settings, where patients often have complex comorbidities and medication regimens. The authors discuss relevant clinical challenges and approaches.